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Abstract
Introduction:  The  natural  history  of  patients  with  inactive  hepatitis  B  virus  (HBV)  is  still  unclear,
persisting  doubts  about  the  optimal  management  of  these  patients.
Aim: To  evaluate  the  long-term  outcome  in  a  cohort  of  hepatitis  B  inactive  carriers.
Methods:  We  conducted  a  retrospective  study  in  a  cohort  of  100  HBV  inactive  carriers  (catego-
rized after  quarterly  determinations  of  serum  ALT  and  HBV  DNA  over  one  year)  and  analyzed  the
results of  serial  determinations  of  HBV  DNA  and  alanine  transaminase  (ALT).  The  HBV  DNA  was
quantiﬁed  by  Cobas  TaqMan®.  We  used  the  Spearman’s  rank  correlation  coefﬁcient  to  evaluate
the correlation  between  the  serum  ALT  and  HBV  DNA.
Results:  We  studied  100  HBV  inactive  carriers  (53%  females,  mean  age  48.7  ±  13.8  years,  range
16--77 year).  Vertical  transmission  was  identiﬁed  in  18%.  The  mean  follow-up  time  was  4.6  ±  2.5
(2--13) years.  Two  patients  had  transient  elevation  of  ALT  (alcohol  and  drugs).  We  observed
clearance of  hepatitis  B  surface  antigen  (HBsAg)  in  four  patients  (4%)  and  biological  and  viro-
logical reactivation  in  10%  (from  the  4th  year  of  follow-up).  Mild  lesions  were  found  in  the  12
patients in  whom  liver  biopsy  was  performed;  genotypes  A  and  D  predominated.  Viral  load  and
serum ALT  levels  were  unremarkable  in  90%  of  the  patients.  There  was  no  signiﬁcant  correlation
(p >  0.05)  between  the  values  of  ALT  and  HBV  DNA  throughout  the  follow-up.
Conclusion:  The  management  strategy,  using  both  patterns  of  biochemical  and  virologic  activity,
seems adequate.  The  lack  of  correlation  between  the  values  of  ALT  and  HBV  DNA  caveat  its
effectiveness  and  the  stability  of  the  levels  of  HBV  DNA  and  ALT  in  most  patients  suggests
that the  prognosis  of  the  inactive  carriers,  when  deﬁned  accurately,  is  mostly  benign.  Further
studies, including  ones  with  new  tests  available,  are  needed  to  standardize  and  improve  the
management  of  this  group  of  patients.
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Vírus  da  Hepatite  B
Portadores  Inactivos  do  Vírus  da  Hepatite  B:  Que  Estratégia  de  Follow-up?
Resumo
Introduc¸ão:  A  história  natural  dos  portadores  inactivos  do  vírus  da  hepatite  B  (VHB)  é  ainda
pouco clara,  persistindo  dúvidas  acerca  da  melhor  estratégia  de  seguimento.
Objectivo:  Avaliar  o  outcome  num  coorte  de  portadores  inactivos  VHB.
Métodos:  Estudo  retrospectivo  num  coorte  de  100  portadores  inactivos  do  VHB  (categorizados
após determinac¸ões  seriadas  trimestrais  da  ALT  sérica  e  do  ADN  VHB  durante  1  ano)  através  de
doseamentos  seriados  anuais  do  ADN  VHB  e  da  ALT.  O  ADN  do  VHB  foi  quantiﬁcado  através
do Cobas  TaqMan®.  Utilizou-se  o  coeﬁciente  de  correlac¸ão  estatística  não  paramétrico  de
Spearman para  avaliar  a  existência  de  correlac¸ão  entre  os  valores  séricos  da  ALT  e  do  ADN
VHB.
Resultados:  Dos  100  doentes  incluídos,  53%  são  do  sexo  feminino;  a  idade  média  é  de  48,7±13,8
(16-77) anos.  A  transmissão  vertical  foi  identiﬁcada  em  18%.  A  durac¸ão  média  do  follow-up  é  de
4,6±2,5 (2-13)  anos.  Dois  doentes  apresentaram  elevac¸ão  transitória  da  ALT  (álcool  e  fármacos).
Observou-se  clearance  do  AgHBs  em  4  doentes  (4%)  e  reactivac¸ão  biológica  e  virológica  em  10%  (a
partir do  4◦ ano  de  follow-up).  Foi  realizada  biopsia  hepática  em  12  doentes  que  apresentavam
lesões mínimas.  Os  genótipos  A  e  D  foram  os  mais  comuns.  A  carga  viral  e  os  níveis  séricos
da ALT  mantiveram-se  estáveis  na  maioria  dos  doentes  (90%).  Não  foi  observada  correlac¸ão
signiﬁcativa  (p>0,05)  entre  os  valores  da  ALT  e  do  ADN  do  VHB,  ao  longo  do  follow-up.
Conclusões:  A  estabilidade  dos  níveis  do  ADN  do  VHB  e  da  ALT  na  maioria  dos  doentes  e  a  ausên-
cia de  correlac¸ão  entre  os  valores  da  ALT  e  do  ADN  do  VHB  ressalvam  a  eﬁcácia  desta  estratégia
de follow-up  e  sugerem  que  o  prognóstico  dos  portadores  inactivos,  quando  deﬁnidos  com
rigor, é  sobretudo  benigno.  São  necessários  mais  estudos,  com  novos  e  promissores  métodos,
para optimizar  e  uniformizar  a  abordagem  deste  grupo  de  doentes.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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a. Introduction
nfection  with  hepatitis  B  virus  (HBV)  is  a  major  public  health
roblem,  affecting  about  350--400  million  people  world-
ide.  It  is  endemic  in  Asia,  sub-Saharan  Africa,  the  South
aciﬁc  Region,  Australia,  New  Zealand  and  in  some  popula-
ions  of  South  America  and  the  Middle  East.1,2
Perinatal  infection  or  horizontal  infection  early  in  child-
ood  are  the  main  routes  of  HBV  transmission  in  high
ndemic  areas,  whereas  in  low  endemic  regions,  such  as
estern  countries,  hepatitis  B  is  primarily  a  disease  of
dolescents  and  adults  as  a  result  of  high  risk  sexual  activ-
ty  and  injection  drug  use.3 The  probability  of  becoming
hronically  infected  is  higher  in  individuals  infected  perina-
ally  (90%)  or  during  childhood  (20--30%)  when  considering
tanding  before  an  immature  immune  system  comparing
o  immunocompetent  individuals  infected  in  adulthood
<1%).1,3 Between  15  and  40%  of  chronically  infected  indi-
iduals  may  develop  severe  liver  disease  and  hepatocellular
arcinoma  (HCC),  while  the  remaining  become  inactive
arriers.1
The  natural  history  of  chronic  HBV  infection  can  be
ivided  into  ﬁve  phases,  not  necessarily  sequential,  that
epend  on  the  virus--host  interaction:  (i)  Immune-tolerant
hase:  This  phase  may  persist  for  10--30  years  in  indi-
iduals  infected  perinatally  or  in  the  ﬁrst  years  of  life.
ii)  Immune-reactive  phase  (HBeAg-positive):  This  phase  is
ore  frequent  and/or  more  easily  achieved  in  individuals
h
w
infected  in  adulthood.  (iii)  ‘‘State  of  inactive  HBV  car-
ier’’:  It  may  occur  after  HBeAg  seroconversion  to  anti-HBe.
t  is  characterized  by  the  absence  of  HBeAg  and  pres-
nce  of  anti-HBe,  serum  HBV  DNA  levels  <2000  IU/mL,
ormal  ALT  levels  and  histologically  minimal  or  no  necroin-
ammation,  slight  ﬁbrosis  or  even  normal  liver.  (iv)
BeAg-negative  chronic  hepatitis  B  (v)  HBsAg-negative
hase:  In  these  patients  immunosuppression,  such  as
hemotherapy  or  after  transplantation,  can  lead  to
eactivation  of  hepatitis  B,  hence  antiviral  treatment  is
ndicated.4
HBV  Inactive  carriers,  previously  designated  as  ‘‘healthy
arriers’’,  ‘‘asymptomatic  carriers  of  HBsAg’’,  constitute
he  largest  group  of  patients  chronically  infected  with  HBV.
t  is  estimated  that  about  300  million  individuals  are  in
his  phase.  More  recently  it  has  been  proposed  the  term
‘inactive  carrier  state’’  due  to  the  possibility  of  reversing
his  condition.
The  prognosis  of  the  inactive  carriers  is  usually  benign.
ong-term  follow-up  studies  (up  to  18  years)  show  that  the
ast  majority  has  a  sustained  biochemical  remission  and
ery  low  risk  of  progression  to  cirrhosis  or  hepatocellular
arcinoma  (HCC).2 Rarely,  some  patients,  even  without  cir-
hosis,  can  develop  HCC  during  the  state  of  inactive  carrier
nd,  in  addition,  from  10  to  34%  of  these  patients  may
ave  a spontaneous  reactivation  during  follow-up,  with  or
ithout  sero-reversion  to  HBeAg.  The  risk  of  reactivation
s  higher  in  the  following  years  after  HBeAg  seroconversion
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and  decreases  with  time,  although  it  can  be  present  after
years  of  inactivity.  The  occurrence  of  multiple  episodes  of
reactivation  or  sustained  reactivation  can  cause  progressive
liver  damage  and  even  hepatic  decompensation.5,6 Acute
ﬂares  of  hepatitis  occurring  during  the  inactive  HBsAg  car-
rier  state  should  be  distinguished  from  super-infection  with
other  hepatotropic  viruses  that  may  occur  in  as  many  as
20--30%  and  can  be  associated  with  an  increased  risk  of  ful-
minant  hepatic  failure.2,7 Treatment  is  not  recommended
in  this  group  of  patients,8,9 neither  routine  liver  biopsy,  as
it  was  considered  that  potential  for  histological  lesions  is
minimal.  For  the  follow-up  of  this  particular  group  of  indi-
viduals  with  chronic  HBV  infection  periodic  monitoring  of
ALT  (every  3,  6  or  12  months)  to  detect  reactivation  is  rec-
ommended.  Regarding  HBV  DNA,  recent  data  show  the  need
to  complement  the  value  of  ALT  with  HBV  DNA  to  avoid  mis-
classiﬁcation  of  the  infection  proﬁle,  taking  into  account  the
ﬂuctuations  of  HBV  DNA.
It  was  recently  proposed  the  use  of  HBsAg  quantiﬁcation
for  categorization  of  this  group.  A  study  by  Brunetto  et  al.10
says  that  the  serum  HBV  DNA  and  HBsAg  levels  provide
complementary  information  to  distinguish  HBV  carriers  of
inactive  subjects  in  genotype  D.  The  combination  of  quantiﬁ-
cation  of  HBV  DNA  (<2000  IU/mL)  and  HBsAg  (<1000  IU/mL)
allows  the  identiﬁcation  of  inactive  carriers  with  a  high  diag-
nostic  accuracy  (94.3%),  which  is  comparable  with  annual
monitoring  of  HBV  DNA  and  ALT.  These  data  require  further
analysis.
HBsAg  status  should  be  monitored  to  detect  a  spon-
taneous  seroconversion,  which  is  estimated  to  occur  at
about  0.5--1%  per  year  and  increases  with  age.  Of  these,
just  over  half  acquire  the  anti-HBs  antibody,  suggest-
ing  that  in  these  cases  the  HBV  infection  has  not  been
eliminated,  but  the  production  of  HBsAg  decreased  to
a  value  lower  than  the  sensitivity  of  detection  meth-
ods.
Inactive  carriers  have  a  very  low  risk  of  developing
cirrhosis,  below  0.1  per  100  patient-years.11 The  inac-
tive  carriers  with  cirrhosis  account  for  1%  of  the  total.
In  these  cases,  treatment  is  recommended  to  reduce  this
risk  of  disease  progression.  The  screening  for  cirrhosis  in
inactive  carriers  must  be  systematic,  being  up  to  now
based  only  on  clinical,  analytical  and  imaging  ﬁndings.9
Non-invasive  methods  to  assess  the  presence  of  ﬁbro-
sis,  such  as  elastography  and  serum  tests,  may  prove  to
be  a  more  effective  way  to  detect  suspected  cases  of
cirrhosis.12
Although  the  risk  of  cancer  is  increased  regarding  the
population  not  exposed  to  HBV,  the  overall  risk  is  low  (0.06%
per  year)  hence  systematic  screening  of  HCC  does  not  seem
to  be  justiﬁed.6,13 Regardless  of  the  severity  of  the  underly-
ing  liver  disease,  the  risk  of  HCC  is  negligible  in  Caucasians
inactive  carriers,  but  increases  about  10  times  in  Asian  inac-
tive  carriers.13
2. ObjectiveThe  aim  of  this  study  was  to  evaluate  the  long-term  outcome
of  a  cohort  of  HBV  inactive  carriers,  through  biochemical  and
virological  monitoring
(
e
(49
.  Patients and methods
.1.  Patients
 retrospective  analysis  of  outpatients  of  the  Hepatology
onsultation  between  1997  and  2010  was  performed.  One
undred  patients  were  identiﬁed,  with  criteria  to  be  classi-
ed  as  inactive  carriers  (after  quarterly  determinations  of
LT  and  DNA  HBV  during  one  year).  Patients  with  the  follow-
ng  characteristics  were  included:  presence  of  serum  HBsAg
nd  anti-HBe,  without  HBeAg;  HBV  DNA  levels  <2000  IU/mL;
epeatedly  normal  ALT  levels.  Other  inclusion  criteria  were
bsence  of  evidence  of  infection  with  hepatitis  C  virus
undetectable  anti-HCV),  no  antibodies  of  human  immuno-
eﬁciency  virus,  no  anti- antibodies  and  exclusion  of  other
auses  of  chronic  liver  disease  (alcohol  consumption,  virus,
AFLD,  hepatotoxic  drugs,  chronic  autoimmune  hepatitis,
emochromatosis,  Wilson’s  disease,  and  1-antitrypsin  deﬁ-
iency).
.2.  Methods
he  virological  markers,  including  HBsAg,  HBeAg,  anti-
Bc,  anti-HBe  and  anti-HBs  were  determined  with  standard
rocedures.  Serum  ALT  assays  levels  were  assessed  by
itachi® robot  911,  using  Boehringer-Mannheim® reagents.
he  upper  limit  of  30  IU/mL  for  men  and  19  IU/mL  for
omen  was  used.14 The  HBV  DNA  was  quantiﬁed  by  Amplicor
BV  Monitor® Kit  (Roche)  and  COBAS® AmpliPrep/COBAS®
aqMan® HBV  test  (Roche).
Percutaneous  liver  biopsy  was  performed  in  12  patients.
iver  histology  was  classiﬁed  according  to  the  score  system
eﬁned  by  Ishak  et  al.15 that  includes  a  ﬁbrosis  score  and  a
core  for  necroinﬂammation.
Statistical  analysis  was  performed  with  SPSS  software®
v.11,  5,  SPSS  Inc.,  Chicago,  IL).  For  quantitative  variables
ALT  and  HBV  DNA),  the  coefﬁcient  of  nonparametric  Spear-
an  correlation  was  used.
.  Results
ne  hundred  HBV  inactive  carriers  were  studied,  of  whom
3%  were  female,  mean  age  48.7  ±  13.8  (16--77)  years.  The
ean  follow-up  period  was  4.6  ±  2.5  (2--13)  years.  Vertical
ransmission  was  identiﬁed  in  18%  of  patients.  Genotypes  A
nd  D  were  the  most  common.  The  characteristics  of  this
roup  of  patients  are  reported  in  Table  1.
During  follow-up,  there  was  an  increase  in  viremia  in
 total  of  33  patients,  but  in  23  of  those  HBV  DNA  levels
emained  below  2000  IU/mL.
There  was  biological  and  virological  reactivation  in  10%
4  men,  6  women)  on  the  4th year  of  follow-up.  Of  these,  all
en  had  an  ALT  value  greater  than  30  IU/L,  at  inclusion,  and
hree  of  the  six  women  had  a  value  greater  than  19  IU/L  and
he  HBV  DNA  was  below  the  limit  of  quantiﬁcation  in  all  of
hem.  No  correlation  between  the  values  of  ALT  and  HBV  DNA
p  >  0.05)  was  observed.  The  increased  viremia  preceded  the
levation  of  ALT  levels  in  six  of  ten  cases.
Clearance  of  HBsAg  was  documented  in  four  patients
4%)  (2  men,  2  women)  who  showed  persistently  normal  ALT
50  
Table  1  Clinical  and  demographic  data  of  patients
included  in  the  study.
Demographic  characteristics
Men/women  47/53
Mean  age  (years)  48.7  ±  13.8  [16;  77]
Mean  follow-up  (years)  4.6  ±  2.5  [2;  13]
Mode of  transmission
Unknown  58
Mother  to  child/intra-familial 18/4
Sexual  14
Percutaneous  6
Genotype
Unknown  82
Most  common  D(6),  A(6)
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ELiver  biopsy,  n  =  12 Mild  histological  lesions
alues  and  HBV  DNA  <20  IU/mL,  except  in  one  case  that
howed  a  transient  viremia  rise  in  the  year  prior  to  clear-
nce,  although  with  a  value  lower  than  2000  IU/mL.  We  were
nable  to  determine  the  time  of  infection  in  this  group.
hree  of  the  patients  became  anti-HBs  positive.
Two  male  patients  presented  transient  elevation  of  ALT,
ne  of  them  in  the  context  of  alcohol  consumption  and  the
ther  because  of  drug  hepatotoxicity  (amoxicillin  and  clavu-
anic  acid).
In  the  12  patients  in  whom  liver  biopsy  was  performed,
istologic  activity  was  mild,  without  ﬁbrosis  (Ishak  <6).
There  was  no  case  of  liver  disease  progression,  particu-
arly  with  cirrhogenic  evolution  or  diagnosis  of  HCC.
. Discussion
his  study  was  performed  in  a  homogeneous  and  large
ohort  of  HBV  inactive  carriers.  The  correct  identiﬁcation
f  the  inactive  carriers  has  important  prognostic  implica-
ions,  since  these  patients  survival  is  comparable  to  that
f  non-infected  population,  at  least  in  Western  studies.
ccording  to  international  guidelines,  a correct  approach
o  chronic  HBV  infection  requires  an  accurate  differential
iagnosis  between  chronic  hepatitis  and  the  inactive  car-
iers  through  the  serial  (quarterly)  determination  of  ALT
evels  and  HBV  DNA  for  at  least  one  year.  Some  data  suggest
hat  the  use  of  HBV  DNA  and  ALT  alone  to  deﬁne  an  inac-
ive  carrier,  without  resort  to  liver  biopsy,  may  not  detect
igniﬁcant  histological  disease  in  about  10%  of  patients.16
ased  on  this,  liver  biopsy  was  performed  in  only  12  patients.
e  acknowledge  this  as  limitation,  as  it  is  a  retrospective
tudy,  although  the  results  are  similar  to  other  studies  that
onsider  there  is  minimal  or  no  necroinﬂammatory  activity
n  the  inactive  carrier  state.  Since  liver  biopsy  is  seldom
ecommended  in  these  patients,  there  are  few  conﬁrma-
ions  of  these  ﬁndings  and  liver  histologic  changes  in  this
roup  are  difﬁcult  to  assess.  As  liver  biopsy  is  an  invasive
ethod  of  evaluating  liver  ﬁbrosis,  and  carries  small  risk
f  complications,  we  consider  appropriate  to  not  routinely
erform  biopsy  in  these  asymptomatic  group  of  patients.17
espite  some  limitations,  transient  elastography  appears  an
deal  approach  for  identifying  liver  ﬁbrosis  in  all  inactive
P
d
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arriers.17 Recent  studies  on  HBsAg  level  in  different  pop-
lation  of  chronic  HBV  infection  have  shown  that  HBsAg
evel  is  lowest  in  the  inactive  carrier  patient  and  HbsAg
uantitation  may  help  to  differentiate  between  active  and
nactive  HBeAg-negative  HBsAg  carrier  state.  The  combina-
ion  of  serum  HBsAg  and  HBV  DNA  levels  shows  promising
esults  as  a  single-point  measurement,  instead  of  quarterly
aboratorial  monitoring  over  a  year,  for  identifying  inactive
arriers.10,13,16--20
The  results  show  that  in  90%  of  patients  most  (77%)  had
o  detectable  serum  HBV  DNA  and  23%  had  levels  below
000  IU/mL.
In  the  Western  countries,  the  reactivation  is  rare  and
hen  it  occurs  is  due  mainly  to  the  presence  of  cofactors
uch  as  alcohol  or  drugs.  Signiﬁcant  predictors  of  mortal-
ty  in  HBsAg-positive  patients  are  the  presence  of  medical
omorbidities,  older  age  at  diagnosis,  and  abnormal  GGT
evels.1,21--23 Another  study  concluded  that  the  majority  of
nactive  carriers  have  a low  level  of  viral  replication.24
HBV  reactivation  occurred  in  ten  of  our  patients,  which
s  in  line  with  published  data  that  estimate  that  reactivation
ccurs  in  10--34%  of  these  patients.25,26
Spontaneous  loss  of  HBsAg  is  about  1--3%  per  year  and  HCC
s  rare.9,16 There  was  clearance  of  HBsAg  in  4%  of  patients
nd  seroconversion  occurred  with  the  appearance  of  anti-
Bs  in  three  patients.  In  these  patients,  the  persistently
ormal  values  of  ALT  and  HBV  DNA  <2000  IU/mL  suggest  that
he  loss  of  HBsAg  may  occur  below  the  threshold  of  HBV
eplication,  but  it  does  not  mean  virus  eradication.  It  was
eported  that  HBV  DNA  can  still  be  detected  with  PCR  in
atients  with  chronic  hepatitis  B  who  develop  HBsAg  sero-
onversion  either  spontaneously  or  after  therapy,  although
 longer  follow-up  is  necessary  to  conﬁrm  this  result.24,27
The  results  of  the  present  study  show  that  serial  monitor-
ng  with  persistently  normal  ALT  values  and  HBV  DNA  level
2000  IU/mL  in  HBeAg-negative  HBsAg  seropositive  persons
re  appropriate  criteria  to  deﬁne  ‘‘HBV  inactive  carriers’’.
he  follow-up  and  outcome  suggest  that  the  prognosis  of
BV  inactive  carriers,  when  accurately  deﬁned,  is  benign.
. Conclusion
he  natural  history  of  the  HBV  inactive  carriers  is  not  totally
lear  and  there  are  few  studies  about  this  group.  The
rognosis  is  generally  good,  but  the  risk  of  reactivation,
nd  consequent  liver  disease  complications  namely  HCC,
emains  present  even  after  several  years  of  inactivity.28
hus,  a  surveillance  strategy  is  needed.  With  this  study,
sing  the  recommended  strategy  of  regularly  monitor  ALT
nd  viremia,  we  found  similar  results  to  previously  published
ata.
It  is  our  believe  that  more  studies  with  large  cohorts  are
eeded  to  deﬁne  the  most  adequate  management  strategy
o  these  patients,  including  data  about  the  promising  AgHBs
uantiﬁcation  and  transient  elastography.
thical responsibilityrotection  of  human  and  animal  subjects.  The  authors
eclare  that  no  experiments  were  performed  on  humans  or
nimals  for  this  study.
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